Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kedrion human plasminogen eye drops for ligneous conjunctivitis
2012-001340-21Phase 2Completed
- Sponsor
- Kedrion Biopharma
- Start
- Oct 2012
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of plasminogen in ligneous conjunctivitis and plasminogen deficiency type 1 (PLGD1) (3 arms), sponsored by Kedrion Biopharma. Primary endpoints: Prevention of pseudomembrane recurrence during Segment 2 and Clinical safety. Started Oct 2012; status: completed.
02
Drugs
plasminogen
03
Conditions
ligneous conjunctivitisplasminogen deficiency type 1 (PLGD1)
Beyond the preview
Go deeper on 2012-001340-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001340-21.